About this trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Determine the Efficacy, Safety, and Dosing of TG-C in Adult Subjects with Symptomatic Early Hip Osteoarthritis. TG-C will be administered to the target hip by a single ultrasound (or fluoroscopy)-guided, intra-articular injection with image capture showing correct injection of study drug into the femoroacetabular joint. Patients will be followed for 12 months for safety and efficacy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged 18 to 80 years old
The subject has a diagnosis of Grade ≤2 primary OA of the target hip
Pain ≥ 40 on VAS scale
The subject has groin pain that is elicited by hip rotation on physical examination
Disqualifiers
The subject exhibits severe symptoms in the target hip that result in difficulty or an inability to walk.
The subject has severe hip OA ipsilateral to the target hip.
Previous cartilage transplantation procedure to the injured cartilage surface.
Major injury to the target hip within 12 months of screening.
Trial design
Parallel
Treatments tested in this trial
TG-C
Biological/Vaccine2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.
Placebo Control
Biological/Vaccine2 mL normal saline injection
Treatment groups
Trial outcomes
Primary outcomes
Change in Hip Pain as Assessed by VAS
Assessment of change from baseline in target hip pain using the Visual Analog Scale (VAS). The VAS is a method for the assessment of the intensity of pain. The VAS is a horizontal line, 100 mm in length and anchored by word descriptors at each end (no pain, very severe pain). The patient marks on the line at the point that represents their current state. The VAS score is determined by measuring in millimeters from the left hand end to the point of the mark. The score ranges from "0" or no pain to "100" very severe pain.
Secondary outcomes
Hip Disability and Osteoarthritis Outcome Score (HOOS)
The HOOS questionnaire was built upon the Western Ontario and MacMaster Universities Osteoarthritis Index (WOMAC®). Questions from the WOMAC® were used as the basis for the survey, and 2 dimensions were added: sport and recreation and hip-related quality of life. The HOOS is composed of 40 questions in 5 subscales: Pain (10 items), Symptoms (5 items), Activity of Daily Living (17 items), Sport and Recreation Function (4 items), and Hip-Related Quality of Life (4 items). A total score, ranging from 0 to 100 is calculated. Higher scores represent better functioning.
Timed Up and Go Test (TUG)
The TUG test is used to determine the time needed to progress from sitting to standing and walking. In addition, the test helps to evaluate the probability for falls. The individual starts in a seated position in a chair with armrests and, upon command, stands up, walks 3 meters, turns around, walks back to the chair, and sits down. The time stops when the subject is seated. The use of walking aids should be recorded and kept consistent between tests.
UCLA Activity Score
The UCLA Activity Score includes 10 statements that cover the range of activity states from being "wholly inactive, dependent on others, and cannot leave residence" to "regularly participate in impact sports." The respondents are instructed to select one statement that is most representative of their current activity. Lower scores on the scale reflect a low level of activity and higher scores reflect more activity.
Joint Space Width (JSW) on standing X-ray
To evaluate the effects of 2 dose levels of TG-C on the structural features of the hip joint
Other outcomes
Physical Component Score (PCS) of the Short Form 12-Item Health Survey (SF-12 Questionnaire)
Evaluation the Health-Related Quality of Life (HRQoL) as measured by the physical component score (PCS) of the 12-Item Short-Form Health Survey version 2 (SF-12v2®) questionnaire addresses physical functioning, role-physical, bodily pain, general health perceptions, vitality, social functioning, role-emotional, and mental health. The mean score is set to 50. Scores \>50 indicate better physical or mental health than the mean, and scores \<50 indicate worse physical or mental health than the mean.
Clinician Global Impression of Change (CGI-C)
The CGI-C asks clinicians to choose the response that best describes the overall change in the patient's OA since they received the study medication as "much better," "moderately better," "a little better," "no change," "a little worse," "moderately worse," or" much worse." Clinicians are also asked to indicate if the change that the patient has experienced is clinically meaningful.
Clinician Global Impression of Severity (CGI-S)
clinician to choose the response that best describes the severity of the patient's overall OA as "none," "mild," "moderate," or "severe."
Patient Global Impression of Severity (PGI-S)
patients to select the response that best describes the severity of their OA, their OA-related pain, and their OA-related stiffness and their difficulty with activities as a result of their OA as "none," "mild," "moderate," or "severe."
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: